Dale Gerding News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dale gerding. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dale Gerding Today - Breaking & Trending Today
Destiny Pharma PLC hails study that underlines safety of lead asset proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Scientific Advisor Gerding chairs C Diff symposium investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Proactive headlines: e-therapeutics PLC, ZAIM Credit Systems PLC, I3 Energy PLC… proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
CEO Neil Clark said: "We have made significant progress since closing the £10.4mln equity funding in December 2020 that enabled the NTCD-M3 acquisition.” ....
Update on the recently acquired NTCD-M3 programme Destiny Pharma plc ( Destiny Pharma or the Company ) Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficileinfections Brighton, United Kingdom - 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficileinfection (CDI) recurrence. Following the successful fundraising of £10.4 million in November 2020 and completion of the acquisition of NTCD-M3, Destiny Pharma has commenced the work required to prepare for the Phase 3 clinical study that is scheduled to start in 2022. ....